FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
biopharma-reporter5d
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
The Pharma Letter6d
Novartis’ Kisqali cleared for expanded indication by FDA
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential and FDA Approval
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...
cnbctv186d
USFDA approves Novartis' Kisqali for early-stage breast cancer treatment
This approval marks a breakthrough for individuals diagnosed with hormone receptor-positive (HR+)/HER2-negative stage II and ...
Pharmabiz5d
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
Daily6d
USFDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination ...
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Business Insider6d
Maintaining Hold on Novartis: Kisqali’s Approval Meets Expectations Amid Patent Risks
Graham Parry has given his Hold rating due to a combination of factors surrounding Novartis AG’s recent approval of Kisqali. The drug’s approval for use in early breast cancer with a broad label was ...
healthday on MSN6d
FDA Expands Use of Breast Cancer Drug Kisqali
Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, fo ...